Delayed
OTC Markets
10:12:50 22/05/2024 pm IST
5-day change
1st Jan Change
0.0055
USD
+66.67%
+34.15%
+5,400.00%
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Acura Pharmaceuti...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC
26/03
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC
14/03
CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC
14/02
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding
14/02
CI
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note
21/12
CI
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors
26/23/26
CI
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets
01/23/01
CI
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03
31/23/31
CI
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement
16/23/16
CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC
29/23/29
CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
30/23/30
CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
30/23/30
CI
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
30/23/30
CI
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC
28/23/28
CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from Abuse Deterrent Pharma, LLC
26/23/26
CI
Acura Pharmaceuticals, Inc. Provides Development Update on LTX-03
13/23/13
CI
Acura Pharmaceuticals, Inc. Announces First Clinical Study for Its Investigational Drug LTX-03
03/23/03
CI
Acura Pharmaceuticals, Inc. announced that it has received $2.319279 million in funding from Abuse Deterrent Pharma, LLC
10/22/10
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding
13/22/13
CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from John Schutte
26/22/26
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding
23/22/23
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.15 million in funding
18/22/18
CI
Acura Pharmaceuticals, Inc Enters into License, Development and Commercialization Agreement with Abuse Deterrent Pharmaceuticals LLC
15/22/15
CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from John Schutte
11/22/11
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding
20/22/20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
More about the company
1st Jan change
Capi.
+5,400.00% 365K +10.55% 115B +12.08% 106B -5.21% 24.69B -2.33% 21.97B -6.03% 19.27B -13.41% 17.56B -40.50% 17.32B +5.80% 14.03B +30.63% 12.13B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1